GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Notable Labs Ltd (NAS:NTBL) » Definitions » Debt-to-EBITDA

Notable Labs (Notable Labs) Debt-to-EBITDA : -0.14 (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Notable Labs Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Notable Labs's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.52 Mil. Notable Labs's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.53 Mil. Notable Labs's annualized EBITDA for the quarter that ended in Dec. 2023 was $-14.40 Mil. Notable Labs's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.14.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Notable Labs's Debt-to-EBITDA or its related term are showing as below:

NTBL' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.14   Med: -0.11   Max: -0.03
Current: -0.14

During the past 3 years, the highest Debt-to-EBITDA Ratio of Notable Labs was -0.03. The lowest was -0.14. And the median was -0.11.

NTBL's Debt-to-EBITDA is ranked worse than
100% of 276 companies
in the Biotechnology industry
Industry Median: 1.37 vs NTBL: -0.14

Notable Labs Debt-to-EBITDA Historical Data

The historical data trend for Notable Labs's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Notable Labs Debt-to-EBITDA Chart

Notable Labs Annual Data
Trend Dec21 Dec22 Dec23
Debt-to-EBITDA
-0.11 -0.03 -0.14

Notable Labs Semi-Annual Data
Dec21 Dec22 Dec23
Debt-to-EBITDA -0.11 -0.03 -0.14

Competitive Comparison of Notable Labs's Debt-to-EBITDA

For the Biotechnology subindustry, Notable Labs's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Notable Labs's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Notable Labs's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Notable Labs's Debt-to-EBITDA falls into.



Notable Labs Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Notable Labs's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.523 + 1.526) / -14.4
=-0.14

Notable Labs's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.523 + 1.526) / -14.4
=-0.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is one times the quarterly (Dec. 2023) EBITDA data.


Notable Labs  (NAS:NTBL) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Notable Labs Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Notable Labs's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Notable Labs (Notable Labs) Business Description

Traded in Other Exchanges
N/A
Address
320 Hatch Drive, Foster City, CA, USA, 94404
Notable Labs Ltd is a clinical-stage platform therapeutics company developing predictive precision medicines for patients with cancer. Through its proprietary Predictive Precision Medicines Platform (PPMP), Notable bio-simulates a cancer treatment to predict whether or not a patient is likely to respond to that specific therapeutic. Through its proprietary Predictive Precision Medicines Platform (PPMP), Notable bio-simulates a cancer treatment to predict whether or not a patient is likely to respond to that specific therapeutic.